West Pharmaceutical ServicesWST +1.66%95 PE Ratio (TTM) is 45.72 as of Jun. 24, 2026, which is 0% above its 10-year median of 45.61. GuruFocus rates WST with a GF Score™ of 95/100 and a GF Value™ of $361.52 (Fairly Valued). The stock has 9 warning signs investors should review. Among 437 Medical Devices & Instruments companies, West Pharmaceutical Services ranks worse than 72.77% on this metric.
During the past 12 months, West Pharmaceutical Services's average EPS without NRIGrowth Rate was 20.00% per year.
During the past 3 years, the average EPS without NRIGrowth Rate was -5.30% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 3.90% per year.
During the past 10 years, the average EPS without NRIGrowth Rate was 17.60% per year.
During the past 13 years, West Pharmaceutical Services's highest 3-Year average EPS without NRI Growth Rate was 47.70% per year. The lowest was -22.60% per year. And the median was 11.00% per year.
West Pharmaceutical Services (NYSE:WST) PE Ratio (TTM) Explanation
The PE Ratio (TTM) can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio (TTM) is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.
In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio (TTM) is positive. Also for stocks with the same PE Ratio (TTM), the one with faster growth business is more attractive.
If a company loses money, the PE Ratio (TTM) becomes meaningless.
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio (TTM) divided by the growth ratio. He thinks a company with a PE Ratio (TTM) equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio (TTM) of 20, instead of a company growing 10% a year with a PE Ratio (TTM) of 10.
Because the PE Ratio (TTM) measures how long it takes to earn back the price you pay, the PE Ratio (TTM) can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.
Investors need to be aware that the PE Ratio (TTM) can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio (TTM)s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio (TTM) is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .
PE Ratio (TTM) can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio (TTM).
West Pharmaceutical Services PE Ratio (TTM) Related Terms
West Pharmaceutical Services PE Ratio (TTM) Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, West Pharmaceutical Services's PE Ratio (TTM), along with its competitors' market caps and PE Ratio (TTM) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
West Pharmaceutical Services PE Ratio (TTM) vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, West Pharmaceutical Services's PE Ratio (TTM) distribution charts can be found below:
* The bar in red indicates where West Pharmaceutical Services's PE Ratio (TTM) falls into.
West Pharmaceutical Services PE Ratio (TTM) Calculation
The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.
West Pharmaceutical Services's Share Price of today is $341.96.
West Pharmaceutical Services's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $7.48.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
There are at least three kinds of PE Ratio (TTM)s used by different investors. They are Trailing Twelve Month PE Ratio (TTM) or PE Ratio (TTM) (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio (TTM) based on inflation-adjusted normalized PE Ratio (TTM) is called Shiller PE Ratio, after Yale professor Robert Shiller.
In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.
West Pharmaceutical Services (WST) has a PE Ratio (TTM) of 45.72 as of Jun. 24, 2026. Trailing 12-month P/E ratio is the ratio of share price to a company's trailing 12-month earnings per share. View historical data on West Pharmaceutical Services and its competitors. This is near median its historical median of 45.61. Over the past decade, West Pharmaceutical Services' PE Ratio (TTM) has ranged from 26.01 to 73.28. According to the industry distribution chart, West Pharmaceutical Services ranks #318 out of 437 companies in the Medical Devices & Instruments industry, placing it in the top 72.8%.
Is West Pharmaceutical Services' PE Ratio (TTM) too high?
West Pharmaceutical Services' current PE Ratio (TTM) of 45.72 is near median its 10-year median of 45.61. Over the past 10 years, this metric has ranged from a low of 26.01 to a high of 73.28. The Medical Devices & Instruments industry median PE Ratio (TTM) is 25.63. West Pharmaceutical Services' value of 45.72 is 78.4% above this industry median. Based on the distribution chart, West Pharmaceutical Services ranks #318 out of 437 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, West Pharmaceutical Services has a GF Score™ of 95/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does West Pharmaceutical Services' PE Ratio (TTM) compare to RMD and MDLN?
According to the Medical Devices & Instruments industry distribution chart, West Pharmaceutical Services ranks #318 out of 437 companies for PE Ratio (TTM). This places West Pharmaceutical Services in the lower half of its industry. The industry median PE Ratio (TTM) is 25.63. West Pharmaceutical Services' value of 45.72 is 78.4% above this benchmark. Historically, West Pharmaceutical Services' own PE Ratio (TTM) has ranged from 26.01 to 73.28 over the past decade. While the company's 10-year median is 45.61 vs. the industry median of 25.63, West Pharmaceutical Services has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PE Ratio (TTM) for a Medical Devices & Instruments company?
The median PE Ratio (TTM) among Medical Devices & Instruments companies is 25.63, based on 437 companies in the industry. Companies in the top quartile (top 25%) have a PE Ratio (TTM) significantly above this median, while those in the bottom quartile fall well below. However, PE Ratio (TTM) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. West Pharmaceutical Services's current PE Ratio (TTM) of 45.72 is 78.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PE Ratio (TTM) mean?
A high PE Ratio (TTM) can signal that a stock is expensive relative to its fundamentals. Trailing 12-month P/E ratio is the ratio of share price to a company's trailing 12-month earnings per share. View historical data on West Pharmaceutical Services and its competitors. For the Medical Devices & Instruments industry, the median PE Ratio (TTM) is 25.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. West Pharmaceutical Services's current PE Ratio (TTM) is 45.72, which is near median its own 10-year median of 45.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is West Pharmaceutical Services stock overvalued right now?
Based on GuruFocus' analysis, West Pharmaceutical Services (WST) is currently considered Fairly Valued. The stock's GF Value™ is $361.52, compared to a current price of $341.96 — trading 5.4% below its estimated fair value. The current PE Ratio (TTM) is 45.72, which is near median its 10-year median of 45.61 and 78.4% above the Medical Devices & Instruments industry median of 25.63. West Pharmaceutical Services' overall GF Score™ is 95/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PE Ratio (TTM) calculated?
PE Ratio (TTM) is calculated from a company's financial statements. For West Pharmaceutical Services (WST), the current PE Ratio (TTM) is 45.72 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is West Pharmaceutical Services (WST) Overvalued in 2026?
Based on GuruFocus' analysis, West Pharmaceutical Services stock appears to be undervalued.
The current stock price of $341.96 is trading 5.4% below its estimated GF Value™ of $361.52.
GuruFocus considers West Pharmaceutical Services to be Fairly Valued.
Key valuation signals for WST:
PE Ratio (TTM): 45.72 (near median its 10-year median of 45.61)
GF Value™: $361.52 vs. price of $341.96 (5.4% below fair value)
Industry Position: 78.4% above the Medical Devices & Instruments median (#318 of 437)
No single metric tells the full story. See the WST stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
95GF Score
Get the complete analysis for WST
PE Ratio (TTM) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WST has been successfully added to your 
